Vertex Pharmaceuticals Incorporated (VRTX) Stake Lowered by Virtus ETF Advisers LLC

Share on StockTwits

Virtus ETF Advisers LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 30.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 3,535 shares of the pharmaceutical company’s stock after selling 1,516 shares during the period. Virtus ETF Advisers LLC’s holdings in Vertex Pharmaceuticals were worth $586,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in VRTX. BlackRock Inc. grew its stake in Vertex Pharmaceuticals by 3.2% during the third quarter. BlackRock Inc. now owns 19,935,843 shares of the pharmaceutical company’s stock valued at $3,842,436,000 after acquiring an additional 625,328 shares in the last quarter. Vanguard Group Inc grew its stake in Vertex Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock valued at $3,618,743,000 after acquiring an additional 213,550 shares in the last quarter. FMR LLC grew its stake in Vertex Pharmaceuticals by 10.5% during the third quarter. FMR LLC now owns 18,071,478 shares of the pharmaceutical company’s stock valued at $3,483,097,000 after acquiring an additional 1,714,071 shares in the last quarter. Jennison Associates LLC grew its stake in Vertex Pharmaceuticals by 22.5% during the third quarter. Jennison Associates LLC now owns 6,202,493 shares of the pharmaceutical company’s stock valued at $1,195,468,000 after acquiring an additional 1,139,486 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Vertex Pharmaceuticals by 1.0% during the third quarter. Renaissance Technologies LLC now owns 4,089,117 shares of the pharmaceutical company’s stock valued at $788,136,000 after acquiring an additional 38,500 shares in the last quarter. Hedge funds and other institutional investors own 95.40% of the company’s stock.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 1,289 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $193.00, for a total value of $248,777.00. Following the completion of the transaction, the senior vice president now directly owns 13,938 shares of the company’s stock, valued at approximately $2,690,034. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeffrey M. Leiden sold 32,250 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 4th. The stock was sold at an average price of $186.35, for a total transaction of $6,009,787.50. Following the transaction, the chief executive officer now directly owns 155,815 shares of the company’s stock, valued at $29,036,125.25. The disclosure for this sale can be found here. Insiders sold a total of 57,217 shares of company stock valued at $10,645,753 over the last three months. Corporate insiders own 0.75% of the company’s stock.

Shares of NASDAQ:VRTX traded up $1.61 on Tuesday, reaching $183.14. The company’s stock had a trading volume of 486,075 shares, compared to its average volume of 1,634,607. Vertex Pharmaceuticals Incorporated has a 52-week low of $144.07 and a 52-week high of $195.81. The stock has a market capitalization of $46.34 billion, a P/E ratio of 64.71, a PEG ratio of 2.16 and a beta of 1.65. The company has a quick ratio of 2.88, a current ratio of 2.98 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Tuesday, February 5th. The pharmaceutical company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.24. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The business had revenue of $870.11 million during the quarter, compared to analysts’ expectations of $818.29 million. During the same period last year, the company posted $0.61 EPS. The business’s revenue was up 33.5% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 3.22 earnings per share for the current year.

Several research firms recently weighed in on VRTX. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. BMO Capital Markets raised their target price on shares of Vertex Pharmaceuticals to $234.00 and gave the company an “outperform” rating in a research note on Wednesday, February 6th. Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 26th. Finally, Citigroup cut their target price on shares of Vertex Pharmaceuticals from $206.00 to $205.00 and set a “buy” rating for the company in a research note on Friday, January 4th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals has an average rating of “Buy” and an average price target of $203.76.

TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/4146154/vertex-pharmaceuticals-incorporated-vrtx-stake-lowered-by-virtus-etf-advisers-llc.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AMN Healthcare Services  Issues Quarterly  Earnings Results
AMN Healthcare Services Issues Quarterly Earnings Results
Brokerages Expect Madrigal Pharmaceuticals Inc  to Announce -$0.75 EPS
Brokerages Expect Madrigal Pharmaceuticals Inc to Announce -$0.75 EPS
Populous  Price Reaches $1.22 on Top Exchanges
Populous Price Reaches $1.22 on Top Exchanges
FundRequest  Price Up 12.5% This Week
FundRequest Price Up 12.5% This Week
Franklin Financial Network Inc  Insider Sells $17,088.82 in Stock
Franklin Financial Network Inc Insider Sells $17,088.82 in Stock
Bain Capital Specialty Finance Inc  Director Jeffrey B. Hawkins Buys 1,247 Shares
Bain Capital Specialty Finance Inc Director Jeffrey B. Hawkins Buys 1,247 Shares


Leave a Reply

© 2006-2019 Ticker Report